Good MorningThe rebound in equities is already over. The S&P 500 opened higher on Wednesday but quickly reversed course to close the session with a loss of 0.75%. The move confirms resistance at the short-term EMA and the high likelihood the index will continue to fall. The critical support level for Thursday trading is 5,185; if broken, the index sell-off will gain momentum as it enters a downtrend.
The initial jobless claims figures may impact Thursday's trading. Although the claims figures are rarely market-moving, they may amplify fears of labor market weakness and the risk of a recession. There is little hope for equities in that scenario as the big money will move out of equities and into safer havens until the threat is passed. Featured: Sell these "safe" blue chips immediately (Ad) 
|
Communication Services | |
The Walt Disney Company’s (NYSE: DIS) Q3 results and guidance are solid, leaving many questioning why the stock remains under pressure. The primary reason is a caution that economic pressures will continue to impact demand at the parks. This is critical information because the parks accoun... Read the Full Story |
|
From Our Partners | | Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief.
It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live. | | Watch the full story and see the verified track record for yourself |
|
Markets | | When you make a large purchase, like a house or an automobile, you often need to borrow money to balance your finances. Not everyone has a liquid $400,000 set aside for home ownership, but a more common scenario is a $80,000 down payment and a $320,000 loan from a bank. You get the house, the seller... Read the Full Story |
|
Technology | |
Super Micro Computer Inc. (NASDAQ: SMCI) stock is down more than 13% the morning after it delivered its fourth quarter and full-year 2024 earnings report. The curiosity isn’t why the stock is down but why it shot higher in the immediate aftermath of the report.
The headline numbers were... Read the Full Story |
|
From Our Partners | | Moderna's stock doubled in a single day after its cancer vaccine hit key Phase 3 goals, and Merck jumped too. But according to a former Steve Cohen fund manager, the next big opportunity is not Moderna or Merck.
It is a different kind of company tied to a technology already backed by Elon Musk, Sam Altman, Jeff Bezos, and Peter Thiel. Nvidia's Jensen Huang says it will have a dramatic impact on daily life, while Anthropic's CEO believes it could unlock a century of medical progress in just ten years.
Nature Magazine estimates its potential value at $367 trillion globally, and it is already rolling out across the United States. | | Click here to learn about this new era of medical technology |
|
Industrials | |
Lyft (NASDAQ: LYFT) released its second quarter 2024 earnings report, revealing a remarkable milestone. Lyft’s financial release shows that the company achieved GAAP profitability for the first time in the company's history. However, this triumph was met with a wave of investor caution as Ly... Read the Full Story |
|
Technology | |
Super Micro Computer (NASDAQ: SMCI) shares are imploding due to a knee-jerk reaction to weaker-than-expected margin news. However, the takeaways from the earnings report suggest that margin weakness is fleeting and that this dip is buyable. More to the point, the company’s 10-for-1 forward s... Read the Full Story |
|
From Our Partners | | Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required.
Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away. | | Discover the gold income fund before the next payout date |
|
Utilities | |
Constellation Energy (NASDAQ: CEG) is an energy stock that has benefited significantly from the artificial intelligence rally, with a total return of 57% so far in 2024. The fact that about 67% of the company's energy-producing capacity is from nuclear power plants has spearheaded its rise.
Nuc... Read the Full Story |
|
Consumer Discretionary | |
The stock market has been on a whipsaw in the past few trading days. As the so-called “Carry Trade” is now unwound in Japan after that country’s central bank hiked interest rates, the bottom for the S&P 500 is now further away than most had initially thought. Of course, when ... Read the Full Story |
|
Healthcare | |
Amgen (NASDAQ: AMGN) is a biotechnology firm that has made its way into the weight loss treatment battle. The company’s shares have performed relatively well in 2024, providing a total return of 16%, outpacing its sector and the market. The Health Care Select Sector SPDR Fund (NYSEARCA: XL... Read the Full Story |
|
Communication Services | |
Lumen Technologies (NYSE: LUMN) is known for its legacy telecommunications business. However, recently, Lumen’s stock price has skyrocketed over 150%. The catalyst? A surge in demand for high-capacity fiber optic networks that are crucial for powering the artificial intelligence (AI) boom. H... Read the Full Story |
|
Markets | |
Recent market turbulence has illuminated the intricate and influential carry trade strategy. Over the past week, investors witnessed significant aftershocks from the unwinding of these trades, and the potential for further market shakeouts remains high.
What is the Carry Trade?
The carry trade i... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut. | | View Today's Stock Pick |
|
